Reduced Risk of Corporal Tumors in Patients With Head and Neck Paragangliomas With p.Pro81Leu Mutations
Otolaryngology–Head and Neck Surgery · 2023-09 · 169 (3) · 570-576
DOI: 10.1002/ohn.274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, online erschienen am 07.02.2023. Verfasst von Katherine M Miller und 6 weiteren Autor:innen. Beteiligte Einrichtung: Head and Neck Institute, Cleveland Clinic, Head & Neck Institute, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Paraganglioma, Extra-Adrenal, Paraganglioma, Head and Neck Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Patients with head and neck paragangliomas who are positive for the SDHD p.Pro81Leu ( P81L ) mutation are thought to have a distinct phenotype from other SDHx mutations, but few studies have focused on this mutation. The objective of this study was to determine the hazard of developing a second primary, metastatic, or recurrent paraganglioma in SDHx patients with or without P81L . Study Design Retrospective chart review of 60 patients with head and neck paragangliomas and genetic testing, followed for a median of 9 years.
Setting
Single academic medical center.
Methods
Univariable Cox proportional hazards regression evaluated second primary and recurrent paragangliomas in patients with SDHD P81L, SDHx non‐P81L, and nonhereditary paraganglioma.
Results
This series comprised 31 patients without SDHx , 14 with SDHD P81L , and 15 with other SDHx mutations. At a median 9 years of follow‐up, corporal (not head and neck) second primary paragangliomas occurred in 31% of patients with SDHx non‐ P81L mutations, compared with 0% and 4% of patients with SDHD P81L and without SDHx mutations, respectively. Second corporal paragangliomas were more likely in patients with SDHx non‐ P81L mutations than in those without a mutation (hazard ratio = 5.461, 95% confidence interval: 0.596‐50.030, p = .13).
Conclusion
This is the first study to report a lower likelihood of corporal tumors for patients with head and neck paragangliomas with SDH mutations positive for P81L . Larger studies are needed to determine if head and neck paraganglioma patients with P81L qualify for less intensive imaging surveillance to screen for second primary paragangliomas outside the head and neck.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Head and Neck Institute, Cleveland Clinic, Head & Neck Institute, Cleveland, Ohio, USA.
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Zitieren
APA
Miller, K. M., Sbeih, F., Contrera, K., Reddy, C. A., Marquard, J., Eng, C., & Lorenz, R. R. (2023). Reduced Risk of Corporal Tumors in Patients With Head and Neck Paragangliomas With p.Pro81Leu Mutations. Otolaryngology–Head and Neck Surgery, 169(3), 570-576. https://doi.org/10.1002/ohn.274
Vancouver
Miller KM, Sbeih F, Contrera K, Reddy CA, Marquard J, Eng C, et al. Reduced Risk of Corporal Tumors in Patients With Head and Neck Paragangliomas With p.Pro81Leu Mutations. Otolaryngology–Head and Neck Surgery. 2023;169(3):570-576. doi:10.1002/ohn.274
BibTeX
@article{Miller2023,
author = {Miller, Katherine M and Sbeih, Firas and Contrera, Kevin and Reddy, Chandana A and Marquard, Jessica and Eng, Charis and Lorenz, Robert R},
title = {Reduced Risk of Corporal Tumors in Patients With Head and Neck Paragangliomas With p.Pro81Leu Mutations},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2023},
volume = {169},
number = {3},
pages = {570--576},
doi = {10.1002/ohn.274}
}
EUVIMED